These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Orlandi EM; Rocca B; Pazzano AS; Ghio S Leuk Res; 2012 Jan; 36(1):e4-6. PubMed ID: 21890201 [No Abstract] [Full Text] [Related]
3. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Rasheed W; Flaim B; Seymour JF Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702 [No Abstract] [Full Text] [Related]
4. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma]. Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932 [TBL] [Abstract][Full Text] [Related]
5. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography. Wang HC; Lee CS; Liu TC Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241 [No Abstract] [Full Text] [Related]
13. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Latagliata R; Breccia M; Castagnetti F; Stagno F; Luciano L; Gozzini A; Ulisciani S; Cavazzini F; Annunziata M; Sorà F; Rossi AR; Pregno P; Montefusco E; Abruzzese E; Crisà E; Musto P; Tiribelli M; Binotto G; Occhini U; Feo C; Vigneri P; Santini V; Fava C; Rosti G; Alimena G Leuk Res; 2011 Sep; 35(9):1164-9. PubMed ID: 21705080 [TBL] [Abstract][Full Text] [Related]
14. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review]. Liu B; Wang Y; Mi Y; Wang J Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):581-6. PubMed ID: 25052596 [TBL] [Abstract][Full Text] [Related]
16. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. de Lavallade H; Punnialingam S; Milojkovic D; Bua M; Khorashad JS; Gabriel IH; Chaidos A; Olavarria E; Goldman JM; Apperley JF; Marin D Br J Haematol; 2008 May; 141(5):745-7. PubMed ID: 18331365 [No Abstract] [Full Text] [Related]
17. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Caocci G; Atzeni S; Orrù N; Azzena L; Martorana L; Littera R; Ledda A; La Nasa G Leukemia; 2008 Nov; 22(11):2127-8. PubMed ID: 18463676 [No Abstract] [Full Text] [Related]
18. Double-edged sword of the new cancer therapeutics. Force T Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582 [No Abstract] [Full Text] [Related]
19. New generation leukaemia drugs are on their way. Nelson L Drug Discov Today; 2004 Sep; 9(17):732-3. PubMed ID: 15450235 [No Abstract] [Full Text] [Related]
20. Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor. Yamaguchi M; Munemoto S; Kasada A; Murata R; Ueda M Leuk Res; 2010 Sep; 34(9):e237-9. PubMed ID: 20371117 [No Abstract] [Full Text] [Related] [Next] [New Search]